MYD88 Mutation Analysis
Also known as: Myeloid Differentiation Primary Response 88
Use
MYD88 mutation is the most common genetic abnormality in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), detected in 40% of cases. Mutations are rare in the germinal center B-cell-like (GCB) subtype, so mutation analysis can be useful to differentiate between the ABC and GCB subtypes. The L265P mutation is present in >90% of Waldenstrom's macroglobulinemia (WM) and has been associated with increased risk of progression to WM in IgM MGUS patients. MYD88 is also implicated in susceptibility to BTK inhibitors in the treatment of B-cell neoplasms.
Special Instructions
Not provided.
Limitations
Mutations are rare in the germinal center B-cell-like (GCB) subtype, indicating limitations in detection utility for these cases. Zinc fixatives for FFPE samples should not be used as they may affect results. Accurate specimen labeling is crucial.
New York Approved
Methodology
Sanger
Biomarkers
MYD88
Gene
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
Not provided
Container
EDTA tube
Storage Instructions
Use cold pack for transport.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | Refrigerate before shipping. |
| Frozen | Do not freeze. |